GSK licenses experimental arthritis t...

GSK licenses experimental arthritis treatment for $25M

There are 1 comment on the Local Tech Wire story from Jan 6, 2012, titled GSK licenses experimental arthritis treatment for $25M. In it, Local Tech Wire reports that:

The pharmaceutical giant has exercised an option for an exclusive license to develop ChemoCentryx's investigational drug CCX354, which recently produced positive phase 2 clinical trial results in a study of patients with rheumatoid arthritis.

Join the discussion below, or Read more at Local Tech Wire.

Robson

Toronto, Canada

#1 May 6, 2012

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

ChemoCentryx Discussions

Title Updated Last By Comments
News IPO Preview: ChemoCentryx (May '12) May '12 Robson 1
News GSK Licenses RA Drug from ChemoCentryx (May '12) May '12 Robson 1
News GSK Exercises Option to License ChemoCentryx's ... (May '12) May '12 Robson 1
News GlaxoSmithKline Exercises Option to License Che... (May '12) May '12 Joan 1
News GSK obtains exclusive license to ChemoCentryx's... (May '12) May '12 Joan 1
News Drug developer ChemoCentryx has priced its IPO ... (May '12) May '12 Joan 1
News Market Report, "Diabetic Nephropathy - Pipeline... (May '12) May '12 Joan 1
More from around the web